The preliminary results of performed safety studies in TargetAMD are promising

Several safety studies were planned in TargetAMD and discussed with the regulatory authorities. After finishing successfully the in vitro soft agar assay, we will finish the biodistribution study to exclude systemic biodistribution of our cell product soon. Moreover, the integration study to prove random integration of our gene of interest started positively. By that, we are two crucial steps closer to the clinical trial.

2. March 2016
Categories: Target AMD